Hoth Therapeutics Inc. (HOTH) Prices 1.449M Share Common Offering at $3.45/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
After-Hours Movers 03/23: (GSAT) (VAPO) (PSEC) Higher; (MIST) (BXRX) (HOTH) Lower (more...)
March 23, 2020 5:55 PM EDTToday's After-Hours Movers
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) 75.9% LOWER; announced topline results from its Phase 3, multicenter, randomized, double-blind, placebo-controlled NODE-301 trial of its investigational new drug, etripamil nasal spray, the Company's novel short-acting calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT).
Globalstar, Inc. (NYSE: GSAT) 30% HIGHER; announced that the Third Generation Partnership Project (3GPP) has approved the 5G variant of Globalstars Band 53, which will be known as n53.
Vapotherm (NYSE:... More
Hoth Therapeutics Inc. (HOTH) Announces Proposed Public Offering of Common Stock
March 23, 2020 4:53 PM EDTHoth Therapeutics Inc. (Nasdaq: HOTH), a biopharmaceutical company, today announced that it intends to offer shares of its common stock in a "best efforts" underwritten public offering. The offering is subject to market and other conditions and there can be no... More
Hoth Therapeutics (HOTH)Announces Agreement to Joint Development of Self-Assembling Vaccine for Potential Treatment of Coronavirus
March 23, 2020 8:19 AM EDTHoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has reached an agreement with Voltron Therapeutics, Hoth Therapeuticsto form a joint venture entity (to be named HaloVax) to commence preclinical studies for the development of vaccine prospects to prevent, intercept or treat the Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH).
Hoth and Voltron, with the support of MGH, will work jointly on exploring and developing this SAV technology as a... More
